新天藥業(002873.SZ):獲得貴州省藥監局同意醋青皮配方顆粒等52個品種進入臨牀研究的函
格隆匯5月26日丨新天藥業(002873.SZ)公佈,近日,公司收到貴州省藥品監督管理局下發的《省藥品監管局關於同意貴陽新天藥業股份有限公司“醋青皮配方顆粒”等52個品種進入臨牀研究的函》(黔藥監函〔2020〕304號)。截至公告日,公司先後四次獲批進入臨牀研究的中藥配方顆粒品種共計321個。
近年來中藥配方顆粒市場保持快速增長態勢,公司此次獲得省藥監局同意醋青皮配方顆粒、酒蓯蓉配方顆粒、草豆蔻配方顆粒、白鮮皮配方顆粒、胡黃連配方顆粒等52個品種進入臨牀研究,有利於加快公司完善中藥產業鏈佈局、豐富產品結構、滿足市場需求並進一步擴大品牌效應及市場份額,構建公司新的利潤增長點,實現公司業績的進一步提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.